Equity Overview
Price & Market Data
Price: $3.34
Daily Change: +$0.09 / 2.69%
Range: $3.17 - $3.34
Market Cap: $154,650,016
Volume: 312,691
Performance Metrics
1 Week: 9.15%
1 Month: -7.48%
3 Months: -28.33%
6 Months: -59.56%
1 Year: -86.54%
YTD: -40.04%
Company Details
Employees: 227
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.